Pharmacokinetics and bioavailability of quercetin glycosides in humans

Due to its potentially beneficial impact on human health, the polyphenol quercetin has come into the focus of medicinal interest. However, data on the bioavailability of quercetin after oral intake are scarce and contradictory. Previous investigations indicate that the disposition of quercetin may depend on the sugar moiety of the glycoside or the plant matrix. To determine the influence of the sugar moiety or matrix on the absorption of quercetin, two isolated quercetin glycosides and two plant extracts were administered to 12 healthy volunteers in a four-way crossover study. Each subject received an onion supplement or quercetin-4'-O-glucoside (both equivalent to 100 mg quercetin), as well as quercetin-3-O-rutinoside and buckwheat tea (both equivalent to 200 mg quercetin). Samples were analyzed by HPLC with a 12-channel coulometric array detector. In human plasma, only quercetin glucuronides, but no free quercetin, could be detected. There was no significant difference in the bioavailability and pharmacokinetic parameters between the onion supplement and quercetin-4'-O-glucoside. Peak plasma concentrations were 2.3 +/- 1.5 microg x mL(-1) and 2.1 +/- 1.6 microg x mL(-1) (mean +/- SD) and were reached after 0.7 +/- 0.2 hours and 0.7 +/- 0.3 hours, respectively. After administration of buckwheat tea and rutin, however, peak plasma levels were--despite the higher dose-only 0.6 +/- 0.7 microg x mL(-1) and 0.3 +/- 0.3 microg x mL(-1), respectively. Peak concentrations were reached 4.3 +/- 1.8 hours after administration of buckwheat tea and 7.0 +/- 2.9 hours after ingestion of rutin. The terminal elimination half-life was about 11 hours for all treatments. Thus, the disposition of quercetin in humans primarily depends on the sugar moiety. To a minor extent, the plant matrix influences both the rate and extent of absorption in the case of buckwheat tea administration compared with the isolated compound. The site of absorption seems to be different for quercetin-4'-O-glucoside and quercetin-3-O-rutinoside. The significance of specific carriers on the absorption of quercetin glycosides, as well as specific intestinal beta-glucosidases, needs to be further evaluated.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Labbe, M. Provencal, S. Lamy, D. Boivin, D. Gingras, and R. Beliveau The Flavonols Quercetin, Kaempferol, and Myricetin Inhibit Hepatocyte Growth Factor-Induced Medulloblastoma Cell Migration J. Nutr., April 1, 2009; 139(4): 646 - 652. [Abstract] [Full Text] [PDF]

				S. Egert, S. Wolffram, A. Bosy-Westphal, C. Boesch-Saadatmandi, A. E. Wagner, J. Frank, G. Rimbach, and M. J. Mueller Daily Quercetin Supplementation Dose-Dependently Increases Plasma Quercetin Concentrations in Healthy Humans J. Nutr., September 1, 2008; 138(9): 1615 - 1621. [Abstract] [Full Text] [PDF]

				A. M. Cartwright, E.-K. Lim, C. Kleanthous, and D. J. Bowles A Kinetic Analysis of Regiospecific Glucosylation by Two Glycosyltransferases of Arabidopsis thaliana: DOMAIN SWAPPING TO INTRODUCE NEW ACTIVITIES J. Biol. Chem., June 6, 2008; 283(23): 15724 - 15731. [Abstract] [Full Text] [PDF]

				W. Wiczkowski, J. Romaszko, A. Bucinski, D. Szawara-Nowak, J. Honke, H. Zielinski, and M. K. Piskula Quercetin from Shallots (Allium cepa L. var. aggregatum) Is More Bioavailable Than Its Glucosides J. Nutr., May 1, 2008; 138(5): 885 - 888. [Abstract] [Full Text] [PDF]

				D. Kook, A. H. Wolf, A. L. Yu, A. S. Neubauer, S. G. Priglinger, A. Kampik, and U. C. Welge-Lussen The Protective Effect of Quercetin against Oxidative Stress in the Human RPE In Vitro Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1712 - 1720. [Abstract] [Full Text] [PDF]

				J. Carlstrom, J. D. Symons, T. C. Wu, R. S. Bruno, S. E. Litwin, and T. Jalili A Quercetin Supplemented Diet Does Not Prevent Cardiovascular Complications in Spontaneously Hypertensive Rats J. Nutr., March 1, 2007; 137(3): 628 - 633. [Abstract] [Full Text] [PDF]

				I. L. F. Nielsen, W. S. S. Chee, L. Poulsen, E. Offord-Cavin, S. E. Rasmussen, H. Frederiksen, M. Enslen, D. Barron, M.-N. Horcajada, and G. Williamson Bioavailability Is Improved by Enzymatic Modification of the Citrus Flavonoid Hesperidin in Humans: A Randomized, Double-Blind, Crossover Trial J. Nutr., February 1, 2006; 136(2): 404 - 408. [Abstract] [Full Text] [PDF]

				B. A. Graf, W. Mullen, S. T. Caldwell, R. C. Hartley, G. G. Duthie, M. E. J. Lean, A. Crozier, and C. A. Edwards DISPOSITION AND METABOLISM OF [2-14C]QUERCETIN-4'-GLUCOSIDE IN RATS Drug Metab. Dispos., July 1, 2005; 33(7): 1036 - 1043. [Abstract] [Full Text] [PDF]

				F. Fusi, G. Sgaragli, and S. Saponara Mechanism of Myricetin Stimulation of Vascular L-type Ca2+ Current J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 790 - 797. [Abstract] [Full Text] [PDF]

				W. Watjen, G. Michels, B. Steffan, P. Niering, Y. Chovolou, A. Kampkotter, Q.-H. Tran-Thi, P. Proksch, and R. Kahl Low Concentrations of Flavonoids Are Protective in Rat H4IIE Cells Whereas High Concentrations Cause DNA Damage and Apoptosis J. Nutr., March 1, 2005; 135(3): 525 - 531. [Abstract] [Full Text] [PDF]

				K. Brusselmans, R. Vrolix, G. Verhoeven, and J. V. Swinnen Induction of Cancer Cell Apoptosis by Flavonoids Is Associated with Their Ability to Inhibit Fatty Acid Synthase Activity J. Biol. Chem., February 18, 2005; 280(7): 5636 - 5645. [Abstract] [Full Text] [PDF]

				C. Manach, G. Williamson, C. Morand, A. Scalbert, and C. Remesy Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies Am. J. Clinical Nutrition, January 1, 2005; 81(1): 230S - 242S. [Abstract] [Full Text] [PDF]

				P. A Kroon, M. N Clifford, A. Crozier, A. J Day, J. L Donovan, C. Manach, and G. Williamson How should we assess the effects of exposure to dietary polyphenols in vitro? Am. J. Clinical Nutrition, July 1, 2004; 80(1): 15 - 21. [Abstract] [Full Text] [PDF]

				S. Lesser, R. Cermak, and S. Wolffram Bioavailability of Quercetin in Pigs Is Influenced by the Dietary Fat Content J. Nutr., June 1, 2004; 134(6): 1508 - 1511. [Abstract] [Full Text] [PDF]

				C. Manach, A. Scalbert, C. Morand, C. Remesy, and L. Jimenez Polyphenols: food sources and bioavailability Am. J. Clinical Nutrition, May 1, 2004; 79(5): 727 - 747. [Abstract] [Full Text] [PDF]

				S. de Pascual-Teresa, K. L. Johnston, M. S. DuPont, K. A. O'Leary, P. W. Needs, L. M. Morgan, M. N. Clifford, Y. Bao, and G. Williamson Quercetin Metabolites Downregulate Cyclooxygenase-2 Transcription in Human Lymphocytes Ex Vivo but Not In Vivo J. Nutr., March 1, 2004; 134(3): 552 - 557. [Abstract] [Full Text] [PDF]

				R. L Prior Fruits and vegetables in the prevention of cellular oxidative damage Am. J. Clinical Nutrition, September 1, 2003; 78(3): 570S - 578. [Abstract] [Full Text] [PDF]

				R. Cermak, S. Landgraf, and S. Wolffram The Bioavailability of Quercetin in Pigs Depends on the Glycoside Moiety and on Dietary Factors J. Nutr., September 1, 2003; 133(9): 2802 - 2807. [Abstract] [Full Text] [PDF]

				S. Wolffram Reply to Arts, Sesink and Hollman J. Nutr., September 1, 2002; 132(9): 2824 - 2824. [Full Text] [PDF]

				T. Schewe, H. Kuhn, and H. Sies Flavonoids of Cocoa Inhibit Recombinant Human 5-Lipoxygenase J. Nutr., July 1, 2002; 132(7): 1825 - 1829. [Abstract] [Full Text] [PDF]

				Y. Otake, F. Hsieh, and T. Walle Glucuronidation versus Oxidation of the Flavonoid Galangin by Human Liver Microsomes and Hepatocytes Drug Metab. Dispos., May 1, 2002; 30(5): 576 - 581. [Abstract] [Full Text] [PDF]

				S. Wolffram, M. Block, and P. Ader Quercetin-3-Glucoside Is Transported by the Glucose Carrier SGLT1 across the Brush Border Membrane of Rat Small Intestine J. Nutr., April 1, 2002; 132(4): 630 - 635. [Abstract] [Full Text] [PDF]

				T. Walle, U. K. Walle, and P. V. Halushka Carbon Dioxide Is the Major Metabolite of Quercetin in Humans J. Nutr., October 1, 2001; 131(10): 2648 - 2652. [Abstract] [Full Text] [PDF]